Prediction: Broadcom Stock Could Surge by 100% in the Next 3 Years
When looking at stocks with some of the strongest upside potential over the next few years, Broadcom (NASDAQ: AVGO) tops the list. The chipmaker has been caught in the recent market sell-off, down around 20% in 2025 as of this writing. However, the stock is still up more than 45% over the past year.
Let's look at why Broadcom's stock could double, or more, over the next three years.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Broadcom operates in two segments: semiconductor solutions and infrastructure software.
Originally focused solely on hardware, the company entered the software business through various acquisitions over the past few years, including CA Technologies, Symantec, and most recently VMware. With CA Technologies, the company acquired a large portfolio of mainframe and enterprise software solutions, while Symantec brought it an enterprise security business.
It biggest acquisition, though, was VMware, which it acquired in November 2023 for $69 billion. VMWare is a market leader in virtualization and cloud computing solutions. Its core virtualization product allows multiple virtual machines to be run on a single server, helping save customers costs. Meanwhile, its VMware Cloud Foundation (VCF) platform helps customers build hybrid and multicloud environments where they can manage workloads across public clouds and their own on-premise data centers.
Broadcom has set out to transform VMware by streamlining its operations and product solutions, while transitioning customers from perpetual licenses to a subscription model. At the end of its fiscal first quarter, it had transitioned 60% of its customers to a subscription model. In the process, it has also been upselling customers from its compute virtualization product, vSphere, to its VCF platform.
As a result, Broadcom's infrastructure software revenue climbed 47% to $6.7 billion last quarter and it forecast the segment to grow by 23% in fiscal Q2. Its software businesses should be a solid contributor moving forward, especially as enterprise customers start to turn to hybrid cloud environments to run artificial intelligence (AI) workloads.
On the hardware side, Broadcom makes components for various markets, including wireless devices, broadband internet, and automotive. However, its two most important businesses are networking and ASICs (application-specific integrated circuits).
Within its networking business, Broadcom makes components such as ethernet switches, optical receivers, digital signal processors (DSPs), and network interface cards (NICs). These components are critical parts of AI infrastructure.
Ethernet switches let AI chips rapidly exchange massive amounts of data, while optical receivers and DSPs work together to send data across longer distances. NICs, meanwhile, help connect servers to a network. Together, these components are essential in managing the flow of data and distributing AI workloads across servers and ensuring that high-performance computing resources are being best utilized.
As AI chip clusters grow in size and complexity, these components become even more important in helping maintain performance and efficiency.
Given the growing size of AI chip clusters, Broadcom's networking business has strong growth prospects ahead. However, Broadcom's ASICs business represents its biggest opportunity. With this business, Broadcom helps customers create their own custom AI chips designed for specific tasks.
Custom AI chips have better performance and consume less power than the mass-market graphic processing units (GPUs) from Nvidia, which are the primary chips used to train AI models and run inference. The downside is that there are a lot of upfront costs involved and it takes time to design a custom chip. These chips are also less flexible than GPUs, which can be programmed for a variety of tasks.
However, with the skyrocketing cost of Nvidia's GPUs, more companies have been turning to Broadcom to help them design custom AI chips. While custom chips require significant upfront costs, their reduced power consumption can lead to a lower overall cost of ownership over time.
Broadcom's first custom AI chip customer was Alphabet, for which it helped design the Tensor Processing Unit (TPU). These chips were developed specifically to optimize AI workloads within Google Cloud's TensorFlow framework, and have been highly successful at optimizing AI workloads and reducing costs.
Broadcom's success with Alphabet has led to a slew of new custom AI chip customers. The company sees its three AI chip customers furthest along in their development having a $60 billion to $90 billion serviceable market opportunity in its fiscal year 2027 (ending October 2027) alone. Meanwhile, it has added several other custom AI chip customers along the way, including Apple. While Broadcom won't capture this entire market opportunity, it should lead to very strong growth in the coming years.
Broadcom generated $51.6 billion in revenue in fiscal 2024, so if it were able to capture a nice chunk of its custom AI chip opportunity (say, $40 billion in additional revenue) and continue to grow VMware, it perhaps could grow its revenue to surpass $100 billion in fiscal 2027. At a 75% gross margin and few other added expenses, that could add an additional $10 in earnings per share (EPS) to the $4.87 in adjusted EPS it produced in fiscal year 2024.
Let's assume some added expenses and round down its fiscal 2027 EPS to $14.50. With Apple and other customers likely coming on in fiscal 2028, let's assume another $15 billion in revenue growth and add another $2.25 in EPS in fiscal year 2028, bringing the total to $16.75.
With a 25 times forward price-to-earnings (P/E) multiple at the end of 2027 on $16.75 in fiscal 2028 EPS, the stock would be worth more than $400 in three years. The stock currently trades at a forward P/E of near 28 times, so that multiple seems appropriate.
As such, Broadcom's stock looks like it has a nice opportunity to more than double in the coming years helped by a surge in custom AI chip and networking revenue and the continued growth of VMware.
Before you buy stock in Broadcom, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Broadcom wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $594,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $680,390!*
Now, it's worth noting Stock Advisor's total average return is 872% — a market-crushing outperformance compared to 160% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of April 21, 2025
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Geoffrey Seiler has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet, Apple, and Nvidia. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy.
Prediction: Broadcom Stock Could Surge by 100% in the Next 3 Years was originally published by The Motley Fool

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025
Presentation to be webcast live at 10:00 AM ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: 'STSS' and 'STSSW') ('Sharps'), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET. Investors are invited to listen to the presentation and can register here. Sharps recently announced that the Company has commenced shipments under three customer orders tied to previously announced purchase agreements. These shipments represent the Company's first commercial deliveries and its transition to revenue-generating operations. All products are being manufactured and shipped from Sharps' facility in Hungary, which has undergone significant upgrades to support high-volume production. Read the update release HERE. Presentation Details: Event: Q2 Investor Summit Date & Time: 10:00 AM ET on June 10, 2025 Presenter: Robert Hayes, CEO Webcast: LINK HERE Conference Overview and Structure:The Investor Summit is an exclusive event tailored for investors focused on small- and micro-cap stocks. It offers a unique opportunity to meet with management teams from high-potential emerging companies, gain insights from industry experts, and understand how peers are navigating the current market environment. This quarter's event centers on micro-cap companies that are currently undervalued and positioned near catalyst events that could significantly accelerate their growth trajectory. Registration for Investors:To request free registration, please go to the Investor Summit website, ( and click the "Registration" button. For More Information, please visit: or, contact johnna-mae@ About Sharps Technology:Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit FORWARD-LOOKING STATEMENTS:This press release contains 'forward-looking statements'. Forward-looking statements reflect our current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' 'poised' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Investor Contact:Holdsworth PartnersAdam HoldsworthPhone: 917-497-9287Email: IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Top Stock Movers Now: Warner Bros. Discovery, Boeing, Sunnova, and more
U.S. equities were mixed and little changed at midday as the market focused on new trade talks between the U.S. and China. Warner Bros. Discovery will split its TV properties from its streaming and movie studio businesses. Rooftop solar power provider Sunnova Energy International filed for bankruptcy as demand for solar panels in homes tumbles.U.S. equities were mixed and little changed at midday as the markets awaited any news from the trade talks between the U.S. and China that began today. The S&P 500 and Nasdaq rose, but the Dow Jones Industrial Average fell. Warner Bros. Discovery (WBD) was the best-performing stock in the S&P 500 after the media giant announced it was splitting itself into two publicly traded companies, dividing its television properties from its streaming and studio businesses. Shares of Boeing (BA) gained when the aircraft maker landed its first plane in China after the easing of trade tensions with the U.S. led Beijing to allow deliveries of its jets again. Qualcomm (QCOM) shares rose when the chipmaker purchased British-based wired connectivity firm Alphawave for $2.4 billion, boosting its expansion into artificial intelligence (AI) data centers. Intuitive Surgical (ISRG) shares slumped as Deutsche Bank downgraded the stock and lowered the price target, pointing to increased competition for the maker of the da Vinci surgical robot. Shares of The Children's Place (PLCE) sank when the children's products retailer's loss soared and sales fell short of estimates, which it blamed on consumer concerns about the economy and tariffs. Trading in Sunnova Energy International (NOVA) was halted after shares plunged 30% in the premarket when the rooftop solar provider filed for bankruptcy as demand for residential solar panels sinks. Oil and gold futures advanced. The yield on the 10-year Treasury note declined. The U.S. dollar lost ground to the euro, pound, and yen. Prices for most major cryptocurrencies were higher. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The SHIELD II trial is designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with the standard of care (SoC), which includes prophylactic systemic antibiotics, compared to the SoC alone arm in the prevention of post-abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The trial's primary endpoint is measured by the proportion of subjects with a surgical site infection or mortality for any reason within 30 days post-surgery. FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe, and Israel. D-PLEX100, PolyPid's lead product candidate, is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. The trial met the primary efficacy endpoint, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p<0.005). SHIELD II included three key secondary endpoints: The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p<0.005). The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p<0.005). The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1 score >20 in the D-PLEX100 plus SoC arm compared to the SoC alone arm (p<0.05). The ASEPSIS score is a clinical tool used to assess surgical wound infections objectively. The independent Data Safety Monitoring Board raised no safety concerns in SHIELD II. The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in early 2026, with a Marketing Authorization Application in the E.U. to follow shortly thereafter. Price Action: PYPD stock is trading higher by 12% to $3.66 at last check Monday. Read Next:Photo by ittawit21 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.